These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15282678)

  • 21. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
    Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
    Hathirat P; Isarangkura P; Panthangkura W; Chuansumrit A; Sasanakul W; Kanasit R
    Birth Defects Orig Artic Ser; 1988; 23(5B):123-7. PubMed ID: 3390534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac complications in homozygous beta-thalassemia.
    Wonke B; Hoffbrand AV; Aldouri MA; Ward SE
    Prog Clin Biol Res; 1989; 309():51-6. PubMed ID: 2780750
    [No Abstract]   [Full Text] [Related]  

  • 25. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.
    Rashid M; Karimi M
    Transfus Med; 2012 Apr; 22(2):104-7. PubMed ID: 22212011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment.
    Dahlui M; Hishamshah MI; Rahman AJ; Aljunid SM
    Singapore Med J; 2009 Aug; 50(8):794-9. PubMed ID: 19710979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the use of the Cleo 90 infusion set for patients on a palliative care unit.
    Schneider M; Hoffmann M; Lorenzl S
    Int J Palliat Nurs; 2009 Aug; 15(8):372-6. PubMed ID: 19773700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Our experience using "Huber Plus" needles in our infusion center].
    Tazumi K; Kouji K; Matsumura N; Nabetani Y; Kondo M; Tomono K; Mizuki M
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):105-8. PubMed ID: 18195536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
    Koren G; Kochavi-Atiya Y; Bentur Y; Olivieri NF
    Int J Hematol; 1991 Oct; 54(5):371-5. PubMed ID: 1756248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of the "difficult" iron-overloaded patient.
    Martin MB
    Ann N Y Acad Sci; 2005; 1054():516-7. PubMed ID: 16339711
    [No Abstract]   [Full Text] [Related]  

  • 37. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 Jan; 111(5):176-81. PubMed ID: 3943469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of iron overload with a disposable multi-day delivery system.
    Paolo C; Francesco S; Sergio A
    Am J Hematol; 1996 Jan; 51(1):95. PubMed ID: 8571948
    [No Abstract]   [Full Text] [Related]  

  • 40. [Appearance of hematomas after blood extractions related with needle gauge related].
    Segura Ruiz R
    Rev Enferm; 2011 Apr; 34(4):50-2. PubMed ID: 21638891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.